Breaking Down Fagron NV Financial Health: Key Insights for Investors

Startling top-line momentum and solid margins make Fagron's latest figures worth dissecting: Q3 2025 revenues reached €228.2 million (up 6.4% year‑on‑year and +10.3% on a constant exchange rate basis), driven in part by a strong EMEA performance of €86.28 million (+17.3%), while the company reaffirmed a full‑year 2025 revenue outlook of €930-950 million; profitability also improved with net income of €22.78 million (+12.7%), a net margin of 9.57% (+1.59 pp), EBITDA of €43.56 million (+15.5%), EPS of €0.31 and an effective tax rate of 22.48%, against a balance sheet showing total assets of €1.12 billion, liabilities of €613.74 million and equity of €505.40 million (debt/equity 0.80, current ratio 1.76, debt/EBITDA 2.34, interest coverage 7.16 and a net‑debt/EBITDA mid‑term target of 2.8x); valuation sits at a share price of €20.60 (market cap €1.51 billion), P/E 17.61, EV/EBITDA 10.55 and analysts' mean target of €25.31 (+20.24% upside), while key risks include a -2.8% impact from GLP‑1 shortages and regulatory exposure (FDA validations at Wichita showed corrective actions effective), and growth levers range from the University Compounding acquisition and Wichita capacity expansion (each projected to add about $25 million) to a Compounding for Growth plan targeting high single‑ to low double‑digit organic CAGR-dive into the full breakdown below.

Fagron NV (FAGR.BR) - Revenue Analysis

• Q3 2025 total revenues: €228.2 million - +6.4% year-over-year.
• Revenue growth at constant exchange rates (CER): +10.3% year-over-year, indicating currency headwinds masked stronger operational growth.
• Organic growth (normalized, excluding GLP-1 drug shortages) at CER: +8.5%.
• EMEA region outperformed: Q3 2025 EMEA revenues €86.28 million vs €73.56 million in Q3 2024 - +17.3%.
• Company reaffirmed full-year 2025 revenue guidance: €930 million-€950 million.
• Quality/regulatory: FDA inspection at the Wichita facility validated corrective actions - no repeat observations from 2024.

• Revenue drivers: strong EMEA expansion and normalized organic demand once GLP-1 supply effects are excluded.
• Currency impact: reported growth (6.4%) understates underlying performance due to unfavorable FX; CER growth of 10.3% is the better operational indicator.
• Guidance posture: reaffirmation of €930-€950m FY25 shows management confidence in execution and demand stability.
• Operational risk mitigation: successful FDA follow-up inspection reduces regulatory overhang.

Fagron NV (FAGR.BR) Profitability Metrics

• Net income rose to €22.78 million, a 12.70% increase versus Q3 2024.
• Net profit margin improved to 9.57%, up 1.59 percentage points from the prior year.
• EBITDA reached €43.56 million, a 15.50% year-over-year increase.
• Effective tax rate for the quarter was 22.48%, consistent with a stable tax environment.
• Earnings per share (EPS) were €0.31, compared with €0.28 in Q3 2024.

• Margin expansion (net profit margin +1.59 pp) suggests improved cost control or higher-margin sales mix.
• EBITDA growth outpacing net income growth indicates stronger operating performance before non-operating items and taxes.
• Stable effective tax rate at 22.48% reduces volatility in post-tax earnings; EPS benefit is already visible.
• Management guidance indicates a slight full-year 2025 profitability increase, supporting modest upward earnings revisions.

Fagron NV (FAGR.BR) - Debt vs. Equity Structure

• Total assets: €1.12 billion
• Total liabilities: €613.74 million
• Total equity: €505.40 million
• Debt-to-equity ratio: 0.80
• Current ratio: 1.76
• Debt-to-EBITDA: 2.34x
• Interest coverage: 7.16x
• Net debt / EBITDA mid-term target: 2.8x (max 3.5x)

• Leverage posture: With a debt-to-equity of 0.80 and debt/EBITDA of 2.34x, Fagron sits within a conservative-to-moderate leverage band relative to its stated target (2.8x mid-term, 3.5x max), giving room for disciplined M&A or capex.
• Liquidity and coverage: A current ratio of 1.76 and interest coverage of 7.16x reduce refinancing and solvency risk in the near term.
• Strategic flexibility: The equity base of €505.40 million supports balance-sheet resilience and potential equity-funded initiatives while keeping leverage metrics manageable.

Fagron NV (FAGR.BR) - Liquidity and Solvency

• Current ratio: 1.76 - sufficient short-term assets to cover current liabilities with a comfortable margin above 1.5, indicating limited short-term refinancing risk.
• Quick ratio: 1.06 - adequate liquidity excluding inventory, showing the company can meet immediate obligations without relying on stock turnover.
• Debt-to-equity ratio: 0.80 - a balanced capital structure that blends creditor financing with shareholder equity and leaves room for strategic debt-funded initiatives.
• Interest coverage ratio: 7.16 - strong ability to service interest expense (EBIT/Net finance costs), reducing default risk under normal operating conditions.
• Net debt / EBITDA mid-term target: 2.8x - aligned with industry expectations for financial stability while retaining flexibility for M&A or capex.
• Free cash flow conversion target: ≥50% - emphasis on converting earnings into cash, supporting deleveraging and shareholder returns.

Fagron NV (FAGR.BR) Valuation Analysis

Snapshot as of December 12, 2025:

• P/E of 17.61 suggests a moderate earnings multiple-neither deeply discounted nor richly priced versus typical pharma/healthcare peers.
• EV/EBITDA at 10.55 indicates reasonable operational valuation, implying investors pay ~10.6x underlying EBITDA for the enterprise.
• EV/FCF of 18.29 signals a higher valuation relative to free cash flow, highlighting sensitivity to cash generation trends.
• Analyst consensus implies material upside (20.24%) to the €25.31 mean target, which could factor growth expectations or margin improvements.
• Dividend yield (1.70%) provides modest income; the most recent ex-dividend date was May 19, 2025.

For additional corporate context and how Fagron's business model supports these valuation metrics, see Fagron NV: History, Ownership, Mission, How It Works & Makes Money.

Fagron NV (FAGR.BR) - Risk Factors

• GLP-1 drug shortages: In Q3 2025 shortages in the U.S. GLP-1 market reduced Fagron's organic growth by 2.8%, reflecting direct volume declines in compounding formulations and related services. This short-term decline translated into lower topline momentum for the quarter and pressured working capital tied to inventory rebalancing.
• Regulatory inspections & compliance: FDA inspections and similar regulatory actions can interrupt operations, trigger remediation costs, product holds, or require capital investments. Historical remediation episodes in the compounding sector have entailed one-off costs in the low-to-mid millions of euros and temporary revenue losses measured in single-digit percentage points of quarterly sales.
• Currency fluctuations: With multi-jurisdictional exposure, FX swings (EUR/USD, EUR/GBP, BRL, PLN) can alter reported revenue and net margin. A 5% adverse EUR/USD move can reduce reported USD-invoiced revenue by roughly 3-4% on consolidated results, and can compress EBITDA margins by 50-150bps depending on hedging effectiveness.
• Competitive pressures: Increased competition from other compounding labs and pharmaceutical suppliers can pressure pricing and market share, particularly in specialty niches (oncology supportive care, dermatology, GLP-1 adjuncts). Market-share erosion of 1-3% in key segments can translate to similar percentage hits to segment revenue.
• Supply chain disruptions: Interruptions in APIs, raw materials or packaging can raise COGS and reduce availability. Contract manufacturing or alternative sourcing can mitigate but may raise COGS by an estimated 2-6% during acute disruptions.
• Macroeconomic downturns: Recessionary pressures in major markets could reduce elective and higher-margin personalized medicine demand; a 1%-2% GDP decline in key markets can feed through to mid-single-digit reductions in demand for certain compounded therapies.

• Cash flow and liquidity sensitivity: The combined effect of these risks can increase working capital needs (inventory and receivables) and pressure free cash flow; management's liquidity buffers and committed credit lines are key mitigants.
• Mitigation levers: geographic diversification, alternative sourcing, active FX hedging, regulatory compliance investments, and focused R&D or service differentiation can reduce realized impacts.
• Investor considerations: monitor quarterly organic growth trends, regional sales patterns, gross margin evolution, regulatory announcements, and FX translation effects to assess risk crystallization and recovery trajectories.

Fagron NV (FAGR.BR) Growth Opportunities

Fagron NV is pursuing multiple avenues to accelerate revenue and margin expansion. Key initiatives combine inorganic deals, capacity additions approved by regulators, organic compounding growth, and product and geographic expansion.

• Acquisitions and capacity additions delivering near-term revenue boosts.
• Compounding for Growth program targeting sustained organic CAGR.
• New product development and emerging market expansion to expand addressable market.

Priority levers and execution focus:

• Integrate University Compounding Pharmacy quickly to capture the projected €25m revenue stream and cross-sell Fagron products.
• Scale Wichita output to realize the additional €25m by optimizing throughput and addressing any post-validation supply chain bottlenecks.
• Maintain Compounding for Growth discipline to achieve high single-digit to low double-digit organic revenue CAGR at constant exchange rates.
• Target emerging markets with tailored commercial models and regulatory strategies to expand penetration without disproportionate capex.
• Prioritize personalized medicine R&D that leverages existing compounding capabilities to shorten time-to-market and premium pricing potential.
• Pursue bolt-on acquisitions in high-return regions to accelerate market access and capability build-out.

Quantified near-term incremental revenue from committed initiatives:

For a deeper investor-focused profile and stakeholder activity around Fagron NV, see: Exploring Fagron NV Investor Profile: Who's Buying and Why?